Skip Navigation



Human Molecular Genetics Advance Access published online on February 27, 2006
Human Molecular Genetics, doi:10.1093/hmg/ddl038
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
15/7/1225    most recent
ddl038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cardone, M.
Right arrow Articles by Cosma, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cardone, M.
Right arrow Articles by Cosma, M. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved
Received January 13, 2006
Revised February 17, 2006
Accepted February 17, 2006

Article

Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery

Monica Cardone 1, Vinicia Assunta Polito 1, Stefano Pepe 1, Linda Mann 2, Alessandra D'Azzo 2, Alberto Auricchio 1, Andrea Ballabio 1, and Maria Pia Cosma 1 *

1 Telethon Institute of Genetics and Medicine (TIGEM), 80131 Naples, Italy
2 St. Jude Children's Research Hospital, Memphis, TN 38105, USA

* To whom correspondence should be addressed.
Maria Pia Cosma, E-mail: cosma{at}tigem.it


  Abstract

Mucopolysaccharidosis type II (MPSII; Hunter syndrome) is a lysosomal storage disorder caused by a deficiency in the enzyme iduronate 2-sulfatase. At present, the therapeutic approaches for MPSII are enzyme replacement therapy and bone marrow transplantation, although these therapies have some limitations. The availability of new AAV serotypes that display tissue-specific tropism and promote sustained expression of transgenes offers the possibility of AAV-mediated gene therapy for the systemic treatment of lysosomal diseases, including MPSII. We have characterized in detail the phenotype of iduronate-2-sulfatase-deficient mice, a model of human MPSII. These mice display a progressive accumulation of glycosaminoglycans in many organs and excessive excretion of these compounds in their urine. Furthermore, they develop skeleton deformities, particularly of the craniofacial bones, and alopecia, they perform poorly in open field tests, and they have a severely compromised walking pattern. In addition they present neuropathological defects. We have designed an efficient gene therapy approach for the treatment of these MPSII mice. AAV2/8TBG-IDS viral particles were administrated intravenously to adult MPSII mice. The plasma and tissue iduronate 2-sulfatase activities were completely restored in all of the treated mice. This rescue of the enzymatic activity resulted in the full clearance of the accumulated glycosaminoglycans in all of the tissues analyzed, the normalization of the glycosaminoglycan levels in the urine, and the correction of the skeleton malformations. Overall, our findings suggest that this in vivo gene transfer approach has potential for the systemic treatment of patients with Hunter syndrome.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
R. Martin, M. Beck, C. Eng, R. Giugliani, P. Harmatz, V. Munoz, and J. Muenzer
Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)
Pediatrics, February 1, 2008; 121(2): e377 - e386.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Settembre, A. Fraldi, L. Jahreiss, C. Spampanato, C. Venturi, D. Medina, R. de Pablo, C. Tacchetti, D. C. Rubinsztein, and A. Ballabio
A block of autophagy in lysosomal storage disorders
Hum. Mol. Genet., January 1, 2008; 17(1): 119 - 129.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Mingozzi, N. C. Hasbrouck, E. Basner-Tschakarjan, S. A. Edmonson, D. J. Hui, D. E. Sabatino, S. Zhou, J. F. Wright, H. Jiang, G. F. Pierce, et al.
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
Blood, October 1, 2007; 110(7): 2334 - 2341.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.